Cantor Fitzgerald Analysts Give Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) a $14.00 Price Target

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) received a $14.00 target price from analysts at Cantor Fitzgerald in a research report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 145.18% from the stock’s previous close.

AUPH has been the topic of a number of other reports. Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target on the stock. in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. HC Wainwright reduced their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 18th. Finally, BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.28.

Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 5.71 on Friday. The firm’s market capitalization is $475.48 million. Aurinia Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $10.54. The firm has a 50-day moving average of $6.35 and a 200-day moving average of $6.13.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 48,278.23% and a negative return on equity of 50.53%. On average, analysts expect that Aurinia Pharmaceuticals will post ($0.74) earnings per share for the current year.

WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/2801112/cantor-fitzgerald-analysts-give-aurinia-pharmaceuticals-inc-nasdaqauph-a-14-00-price-target.html.

Hedge funds have recently modified their holdings of the stock. Candriam Luxembourg S.C.A. purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $866,000. Hikari Power Ltd purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $440,000. OTA Financial Group L.P. purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $1,291,000. Bank of New York Mellon Corp purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $595,000. Finally, TD Asset Management Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at $241,000. Hedge funds and other institutional investors own 29.48% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.